BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20488540)

  • 1. Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.
    Minarik J; Scudla V; Ordeltova M; Pika T; Bacovsky J; Steinbach M; Kumar V; Van Ness B
    Leuk Res; 2011 Jan; 35(1):44-8. PubMed ID: 20488540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of plasmatic cell proliferation and apoptosis indexes in the course of multiple myeloma].
    Minarík J; Scudla V; Ordeltová M; Bacovský J; Zemanová M; Pika T
    Vnitr Lek; 2008 Jan; 54(1):31-5. PubMed ID: 18390115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
    Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
    Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of plasma cell propidium-iodide and annexin-V indices: their relation to prognosis in multiple myeloma.
    Minarík J; Scudla V; Ordeltová M; Bacovský J; Zemanová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):271-4. PubMed ID: 16601769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
    Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
    Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Leuk Lymphoma; 2009 Dec; 50(12):1983-91. PubMed ID: 19860618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
    Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
    Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
    Moreau P; Robillard N; Avet-Loiseau H; Pineau D; Morineau N; Milpied N; Harousseau JL; Bataille R
    Haematologica; 2004 May; 89(5):547-51. PubMed ID: 15136217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
    Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of multiple myeloma: a report of 182 cases].
    Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell balance between apoptosis and proliferation in colon cancer and its correlation with prognosis].
    Chen JM; Li WH; Wang JD; Feng YD; Wu JH; Gong JP
    Ai Zheng; 2005 May; 24(5):554-8. PubMed ID: 15890096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.